Ocular application

Active molecules currently utilized for ophthalmic applications with poor permeability can be reformulated using LDS’s unique delivery technology. LDS’s nano-sized domains establish significant interfacial contact with the eye epithelium upon topical drop instillation, dramatically enhancing permeation and facilitating its delivery. LDS’s structures can effectively target both the posterior and interior segments of the eye. In addition, LDS technology is capable of solubilizing and deliver large molecular-weight active molecules.

Pre-clinical results demonstrating superiority